Drug Trial Radar · NCT03255694
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
May 12, 2017
Primary completion
Jun 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Tongji Hospital; The First Hospital of Jilin University; Affiliated Hospital of Jiangnan University; The First Affiliated Hospital with Nanjing Medical University; Shanghai Children's Hospital; The Children's Hospital of Zhejiang University School of Medicine; Children's Hospital of Fudan University; Jiangxi Province Children's Hospital; Hunan Children's Hospital; Beijing Children's Hospital; Children's Hospital of Soochow University; Wuxi Women's & Children's Hospital
- First posted
- Aug 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
After the first stage (52 weeks) of Phase II clinical trial, Pegylated recombinant human growth hormone (PEG-rhGH) injection of appropriate dose in compliance with ISS clinical treatment strategy is used to treat children with ISS (Idiopathic Short Stature). The long-term efficacy and safety of the investigational product are evaluated, which can provide more scientific and reliable medication guidance information for clinical diagnosis and treatment.
Conditions
- Dwarfism
Interventions
PEG-somatropinDrug
After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of yearly height velocity (ΔHV)Time frame: Baseline,the end of 3-year addendum
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Children's Hospital of Fudan University
Shanghai, China
Shanghai Children's Hospital
Shanghai, China
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health
Beijing, Beijing Municipality, China
Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Wuhan, Hubei, China
Hunan Children's Hospital
Changsha, Hunan, China
Children's Hospital of Soochow University
Naning, Jiangsu, China
The First Affiated Hospital of Nanjing Medical Universit
Nanjing, Jiangsu, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Wuxi Children's Hospital
Wuxi, Jiangsu, China
Jiangxi Provincial Children's Hospital
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.